Case Report
psoriasis deteriorated after treatment with pembrolizumab. Herein, we reported a patient with preexisting psoriasis vulgaris receiving pembrolizumab experienced the acute exacerbation of psoriasis accompanied with intense myalgia, both of which are responsive to cyclosporine.
CAsE rEport
A 59-year-old male has suffered from esophageal squamous cell carcinoma, T3N2M0, stage IIIB, in the past 2 years. Initially, he underwent six times of concurrent chemoradiotherapy with platinum and 5-fluorouracil (5-FU) with partial remission. However, the tumor recurred several months later and the salvage esophagectomy was performed. After the surgery, he received three times of adjuvant concurrent chemoradiotherapy with Taxotere, cisplatin, and 5-FU, which ended last year (2015) with a complete clinical remission. For his skin, he also has chronic plaque-type psoriasis vulgaris for over 10 years with stable control by oral acitretin 25 mg/day and topical steroids.
He received regular follow-up in oncology clinic for his esophageal cancer until 1 month ago, when the annual positron emission tomography with computed tomography (CT) revealed new tumor growth over left adrenal gland. After discussing with the oncologist, he decided to receive palliative immunotherapy using out-of-pocket pembrolizumab at a dose of 100 mg (2 mg/kg) via intravenous infusion, taking consideration that his performance status was good and the laboratory data reported only mild normocytic anemia (hemoglobin 11.6 g/dL), mildly elevated alkaline phosphate (103 U/L, normal limit: 28-94 U/L), the normal coagulation function, and renal function.
Three days after receiving the first dose of pembrolizumab, he developed painful and generalized erythematous confluent scaly plaques and patches, swelling at distal limbs, and focal erosions over four extremities, abdomen, and back. Severe painful acrodermatitis continua of Hallopeau-like lesions developed at all distal phalanx, causing huge burden both physically and psychologically. The Psoriasis Area Severity Index (PASI) score was 29.9 when he visited our clinic. He also developed severe arthralgia and myalgia over distal extremities [ Figure 1 ]. Neither fever nor oral ulcers were accompanied. No significant new medication or culprit drugs except pembrolizumab were noticed. Under the initial impression of psoriasis exacerbation, skin biopsy was performed on the erythematous plaque at his left lower leg. Histopathology revealed psoriasiform acanthosis of the epidermis, mounds of parakeratosis with neutrophils infiltrate, and moderate lymphocytic infiltrate at upper dermis, all of which indicated the diagnosis of psoriasis vulgaris [ Figure 1 ]. Microscopically, drug eruption can be ruled out because that there was neither basal vacuolated degeneration nor epidermal dyskeratosis.
For his previous history of favorable response to acitretin, we used oral acitretin 50 mg/day and potent topical steroid (Dermovate ® ointment) 10 days after pembrolizumab infusion. However, he developed progressive and severe pruritus with erythema 1 week after oral acitretin, and he could not tolerate those symptoms. Therefore, we replaced acitretin to cyclosporine 200 mg/day. The symptoms started to improve several days after the treatment of cyclosporine. His skin lesions continued to improve 2 months later, and the PASI score decreased to less than 5. He continued to use cyclosporine for the following 5 months to maintain the therapeutic effects of psoriasis until his serum creatinine level elevated from 1.23 mg/dL to 2.01 mg/dL during the cyclosporine treatment.
Owing to the experience of exacerbation of psoriasis, the patient declined any further use of pembrolizumab. He did not receive any further treatment thereafter until a new tumor developed at the posterior pharyngeal wall by regular CT. He received radiotherapy for the tumor control. As for the left adrenal tumor, the follow-up CT revealed a progressive regression 2 months after immunotherapy and in fact, its size was stable after 6 months of follow-up till now. disCussion I n p a t i e n t s w i t h h e a d -a n d -n e c k s q u a m o u s c e l l carcinoma (HNSCC), pembrolizumab is indicated for patients with recurrent or metastatic HNSCC, who has progressive disease or fails to the conventional platinum-containing chemotherapy. As a prototypic drug for the immune checkpoint inhibitor, although anti-PD1 is generally considered to be safer than anti-cytotoxic T-lymphocyte-associated protein-4, which is another checkpoint inhibitor for managing advanced malignancies, the adverse effects of anti-PD-1 are still reported in various clinical settings. [3] However, recent data from clinical trials always excluded patients with preexisting autoimmune diseases. Only limited reports demonstrated patients with preexisting autoimmune diseases deteriorating after treatment with pembrolizumab. [4] [5] [6] Moreover in real-world practices, various irAE effects, such as vitiligo, bullous pemphigoid, autoimmune diabetes, and autoimmune thyroid diseases, occurred even in patients without underlying autoimmune diseases after using anti-PD1. [5, [7] [8] [9] Regardless of the underlying diseases, eczema, lichenoid reaction, and vitiligo are the three most common cutaneous irAE after using immunotherapy, accounting for 25% of patients in the first 10 months. [3] For patients with preexisting autoimmune diseases, the first reported one is a 75-year-old man, with a history of stable-controlled myasthenia gravis (MG), received pembrolizumab 2 mg/kg every 3 weeks due to metastatic BRAF-negative melanoma. After two doses of pembrolizumab, symptoms of MG worsened with progressive diplopia, ptosis, and respiratory distress. Despite the cessation of anti-PD1 and serial rescue treatments such as plasma exchange, intravenous immunoglobulin, and rituximab, the patient passed away 1 month later due to infection. [4] Another study in 2017 enrolled 52 patients receiving anti-PD1 with underlying various AD, such as rheumatic arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, and psoriasis. Among them, 38% of the patients had flares of preexisting AD at a median interval of 38 days after the initiation of anti-PD1 antibody, and most of the AD subtypes are rheumatologic and dermatologic (52% and 38%, respectively). [5] Psoriasis is a chronic inflammatory disorder mediated by T-lymphocytes, dendritic cells, and the complex immune responses. The mechanism of deterioration of psoriasis after using pembrolizumab may correlate with the hyperactive T-cell function induced by pembrolizumab. A recent study by Bonigen et al. included 21 patients with anti-PD1-induced psoriasis. [6] About 30% of patients requiring oral acitretin in additional to conventional topical medications; nearly 4.8% of patients were stable after phototherapy. 90.5% of the patients improved after the treatments, although none of them used cyclosporine for the exacerbated psoriasis. [6] The majority of the patients would go on with anti-PD1 therapy after rescuing management, whereas 19% of them had to stop the anti-PD1 treatment due to intolerance. [6] Besides, there were limited numbers of case reports reported the skin manifestations in psoriatic patients receiving anti-PD-1, and we summarized these case reports from 2016 to 2017 in Table 1 . Twenty-eight patients received anti-PD1 with an average age of 65.9 years old and the underlying advanced malignancies including lung cancer, urothelial carcinoma, and squamous cell carcinoma. Before anti-PD1 therapy, 19 patients had a history of psoriasis; two patients had a family history of psoriasis without personal skin lesions; seven patients did not have psoriasis history at the beginning of anti-PD1 therapy. The interval between the initiation of anti-PD1/PDL1 to the flare of psoriasis ranged significantly, from several days to several months. The most common type of anti-PD1/ PDL1-induced flare of psoriasis is the plaque type, followed by guttate psoriasis, palmoplantar psoriasis, psoriatic arthritis, and erythroderma. Among the 28 patients, 26 (93%) patients were improved after conventional psoriasis treatment, including topical steroid, narrow-band ultraviolet B phototherapy, oral acitretin, and oral MTX. Twenty-four patients (85.7%) of the patients could continue the immunotherapy with topical medications along with systemic acitretin (n = 8) and methotrexate (n = 1).
In this case of PD-1 associated psoriasis, we introduced acitretin initially. However, due to the progressive pruritus, erythema, myalgia, and weakness by acitretin, we replaced it with cyclosporine. Most reported cases of PD-1 associated psoriasis showed a rather good response to acitretin; however, none of them received cyclosporin treatment. The reason why the patient of PD-1 associated psoriasis exacerbation had the discrepancy regarding to the treatment responses to acitretin is not clear; however, the concurrent worsening of the skin lesions with the intolerable myalgia and weakness, in this case, suggested a more systemic immune responses (i.e., irAE) rather than simple skin exacerbation in the previously reported cases. The impact of cyclosporine on the cancer progression is controversial. In an animal study, there was no increased risk of malignancies with cyclosporine at a dose of up to 8 mg/kg/day. [10, 11] Cyclosporine is widely used for the long-term immunosuppressant in transplant patients. However, only skin squamous cell carcinomas but not other internal malignancies were associated with the high dose and long-term use of cyclosporine. [12, 13] Phototherapy is not feasible for this patient because he lives in Penghu, far from the Main island of Taiwan, and he had difficulty visiting the medical facility frequently. Therefore, with appropriate monitoring, cyclosporine could be useful in managing immunotherapy-exacerbated psoriasis.
It was proposed that the severity of the flared psoriasis might be proportional to the tumor response to anti-PD-1. [14, 15] The role of dermatologist in the scenario is to help manage the exacerbation of cutaneous irAE to continue the anti-PD1 treatment.
ConClusion
Pembrolizumab is an uprising drug for late-stage or unresectable cancer, and it may be the last hope for these end-stage patients at this point in current science. The cutaneous adverse effects mainly result from its enhancement of immune functions which leads to the exacerbation of previous immune-related diseases in susceptible patients. We reported a patient with metastatic esophageal cancer and stable status of psoriasis vulgaris, who experienced psoriasis exacerbation, and myalgia 3 days after a single dose of pembrolizumab. The symptoms worsened and were intolerable after acitretin treatment, but they improved soon after its replacement with cyclosporine. The exact mechanism, predicting factors for the onset and severity of irAE, and what appropriate treatment is in patients with psoriasis receiving pembrolizumab remain undefined. More data and clinical experiences are required to provide more compelling information for the patient receiving immunotherapy with anti-PD-1.
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